Bone Transport Accelerates Diabetic Foot Ulcer Healing via TGF-β1–Mediated Angiogenic and Osteo-Immune Coupling

Study Background and Research Question

Chronic diabetic foot ulcers (DFUs) present a persistent challenge in diabetes care due to their poor healing capacity, high rates of infection, and risk of amputation. A major underlying factor is impaired vascularization and persistent inflammation, often complicated by peripheral artery disease and local tissue hypoxia. Bone transport (BT)—a surgical method involving osteotomy and gradual bone distraction—has demonstrated clinical promise for recalcitrant ulcers, based on its dual ability to promote new bone formation (osteogenesis) and new blood vessel growth (angiogenesis). However, the molecular mechanisms by which BT enhances wound healing, especially the role played by the transforming growth factor-beta 1 (TGF-β1) signaling pathway, have remained incompletely understood. This knowledge gap motivated the study by Chen et al. (Journal of Molecular Histology, 2026), aiming to dissect the cellular and molecular processes driving BT-mediated DFU repair.

Key Innovation from the Reference Study

The central innovation of this research lies in its identification of TGF-β1/TGFBR1 pathway activation as the mechanistic driver of improved wound healing following bone transport. By combining proteomics, histology, and immunological profiling, the authors demonstrate that TGF-β1 orchestrates both angiogenic and osteo-immune coupling at the wound site—a dual process critical for robust tissue regeneration. Notably, the study introduces a BT-with-inhibition (BTI) group, in which the TGF-β1 pathway is selectively blocked, establishing direct causality between pathway activation and healing outcomes. This approach enables clear dissection of the TGF-β signaling pathway’s role in coupling bone-driven signals with vascular and immune responses in diabetic wounds.

Methods and Experimental Design Insights

The investigators employed a robust, controlled experimental design using seventy-five Sprague-Dawley rats with chemically induced ischemic DFUs. Animals were randomized into three groups:

• Sham (osteotomy without distraction)
• BT (bone transport)
• BTI (BT with TGF-β1 pathway inhibition)

Wound healing was assessed through serial measurements and histological analysis. To interrogate molecular mechanisms, the study deployed a multi-modal toolkit encompassing:

• Proteomics for unbiased protein expression profiling
• Enzyme-linked immunosorbent assay (ELISA) for quantitative detection of TGF-β1 and VEGF in serum
• Quantitative real-time PCR (RT-qPCR) to measure mRNA expression of key genes
• Immunohistochemistry for localizing protein expression in tissue sections

Importantly, the BTI group received a TGF-β1 pathway inhibitor to delineate the causal contribution of this signaling axis. While the specific inhibitor is not detailed in the reference, analogous research frequently employs selective ALK5 inhibitors such as SB525334 for in vivo and in vitro pathway blockade.

Core Findings and Why They Matter

Bone transport produced marked improvements in wound healing compared with both sham and BTI groups, as evidenced by:

• Accelerated wound closure and increased dermal thickness
• Enhanced re-epithelialization and granulation tissue formation
• Greater upregulation of TGF-β1 and TGFBR1 expression at the wound site
• Elevation of serum and local levels of pro-angiogenic (VEGF) and myofibroblast (α-SMA) markers

Proteomic analysis revealed that BT activated the TGF-β1/TGFBR1 pathway, coinciding with significant complement activation and a balanced inflammatory response. The data indicate that bone transport not only stimulates angiogenesis via TGF-β1 but also facilitates systemic and local immune modulation—an effect termed osteo-immune coupling. This dual action was abrogated in the BTI group, confirming the centrality of TGF-β1 signaling in mediating these reparative effects (reference study).

These findings suggest that targeting TGF-β1 signaling can harness both vascular and immune-regenerative pathways to overcome the otherwise recalcitrant nature of diabetic wounds, positioning the TGF-β1/TGFBR1 axis as a highly promising therapeutic target.

Comparison with Existing Internal Articles

The results of this study are in close agreement with several recent internal reviews and summaries:

• The article "Bone Transport Enhances DFU Healing via TGF-β1 Pathway Coupling" similarly emphasizes the mechanistic link between bone-driven signaling and reparative processes in chronic wounds, highlighting the TGF-β1/TGFBR1 axis as a therapeutic target.
• "Bone Transport Enhances Diabetic Wound Healing via TGF-β1 Coupling" and "Bone Transport Accelerates Diabetic Foot Ulcer Healing via TGF-β1" both reinforce the core message that coupling angiogenesis with osteo-immune modulation via TGF-β1 is essential for tissue repair in DFUs.

Taken together, these articles and the reference paper build a consistent mechanistic framework for understanding how TGF-β1 signaling integrates bone, vascular, and immune responses in regenerative medicine. Moreover, prior workflow articles such as "SB525334: Precision TGF-beta1 Receptor Inhibitor for Fibrosis Models" provide practical guidance on the use of TGF-β1 pathway inhibitors for dissecting these mechanisms in both cellular and animal models, further underscoring the translational potential of this axis.

Limitations and Transferability

While the study's multi-modal approach and use of an established animal model strengthen its conclusions, several limitations merit consideration:

• Rodent DFU models, though informative, do not fully capture the chronicity and complexity of human diabetic wounds, especially with respect to comorbidities and immune diversity.
• The exact inhibitor used for TGF-β1 pathway blockade was not specified, making direct protocol translation dependent on careful reagent selection and dosing optimization.
• Long-term effects and potential off-target consequences of sustained TGF-β1 inhibition (including impacts on systemic immunity and fibrosis) were not addressed.
• Translation to clinical application requires validation in larger animal models and ultimately in human trials.

Nevertheless, the study provides a solid mechanistic rationale for further exploration of TGF-β1 signaling modulation in regenerative and wound-healing contexts, with clear implications for fibrosis research and other chronic tissue injury models.

Protocol Parameters

• Bone transport parameters (rodent): Osteotomy performed at the tibia; distraction rate and rhythm as per Ilizarov protocol; wound measurement every 2–3 days post-operation (reference study).
• TGF-β1 pathway inhibition: Selective ALK5 inhibitors such as SB525334 are commonly used in vivo at doses ranging from 1–10 mg/kg, delivered via oral gavage or intraperitoneal injection, with dosing and timing tailored to the specific animal model and experimental window (internal article).
• Molecular endpoint analysis: RT-qPCR and immunohistochemistry are recommended for confirming pathway modulation (TGF-β1, TGFBR1, VEGF, α-SMA expression) in tissue samples.

Research Support Resources

Researchers seeking to dissect TGF-β1 signaling in diabetic wound repair or fibrosis models can utilize SB525334 (TGF-beta1 receptor inhibitor) (SKU A5602), a potent and selective ALK5 inhibitor. SB525334 is widely used for mechanistic studies of TGF-β signaling, Smad2/3 phosphorylation inhibition, and fibrosis research, and is suitable for both cellular and animal workflows. For full product specifications and handling recommendations, consult the manufacturer’s site. APExBIO provides detailed protocols and practical tips for integrating SB525334 into research on TGF-β1-mediated tissue regeneration and chronic wound models.